Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Michael Bookman is CHIEF LEGAL OFFICER, SECRETARY at Immuneering. OQRO lists 1 transaction filed with the SEC under this name, the latest on Feb 5, 2026, each linked to the official Form 4.
CHIEF LEGAL OFFICER, SECRETARY
Disclosures on record
1
Companies involved
1
ImmuneeringIMRX
Feb 3, 2026176Kdisclosed Feb 5
DetailsOfficial recordMichael Bookman bought shares on the open market in 2021 and 2022, and has not bought since 2022.
Michael Bookman reported 2 open-market purchases and 0 sales since 2021; purchases in 2 different years, most recently 2022.
| Year | Bought | Sold |
|---|---|---|
| 2022 | $4.9K1×1 trade | — |
| 2021 | $21K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Michael Bookman reported 2 open-market purchases and 0 sales here, 2021 to 2022.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
Michael Bookman bought shares on the open market in 2021 and 2022, and has not bought since 2022.
In SEC filings since 2021: the latest open-market purchase is from 2022; no open-market sale is on record.
Immuneering (IMRX), from 2021 to 2022: 2 purchases and 0 sales.